Aripiprazole Lauroxil Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 41 mg, 662 mg, 882 mg, 1064 mg
Reference Brands: Aristada (USA)
Category:
Antipsychotropic Drugs
Aripiprazole Lauroxil Injection is available in Injection
and strengths such as 41 mg, 662 mg, 882 mg, 1064 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aripiprazole Lauroxil Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aripiprazole Lauroxil Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic used for the treatment of schizophrenia in adults. It is a prodrug of aripiprazole, designed to provide sustained therapeutic levels over several weeks, improving adherence in patients who may have difficulty taking daily oral medications. Administered via intramuscular injection every four to eight weeks, aripiprazole lauroxil helps manage symptoms of schizophrenia, including hallucinations, delusions, disorganized thinking, and mood disturbances, by modulating dopamine and serotonin receptor activity in the brain.
Developed by Alkermes, aripiprazole lauroxil is an N-acyloxymethyl prodrug that gradually converts to active aripiprazole in the body, allowing for prolonged efficacy with fewer administrations. It provides a longer-lasting alternative to daily oral aripiprazole tablets, offering consistent symptom control and reducing the risk of relapse due to non-adherence. Aripiprazole lauroxil, like other antipsychotics in its class, is not approved for the treatment of dementia-related psychosis in elderly patients. Its extended-release formulation and predictable pharmacokinetics make it a valuable option in the long-term management of schizophrenia.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing